What is Becton, Dickinson and Company's market cap?

Becton, Dickinson and Company (BDX) has a market capitalization of $41.6B and trades on NYSE.

What is Becton, Dickinson and Company's revenue and profitability?

Becton, Dickinson and Company generated $21.4B in trailing twelve-month revenue with net income of $1.1B, representing a net margin of 5.3%. Gross margin stands at 46.8%, with free cash flow of $3.5B. These figures are based on the Q1 2026 filing.

Who are Becton, Dickinson and Company's competitors?

Becton, Dickinson and Company's key competitors include Baxter International, Abbott Laboratories, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.

Who does Becton, Dickinson and Company partner with?

Becton, Dickinson and Company's notable partners include Microsoft.

What subsidiaries does Becton, Dickinson and Company have?

Becton, Dickinson and Company's subsidiaries include C. R. Bard, CareFusion.

Where is Becton, Dickinson and Company headquartered?

Becton, Dickinson and Company is headquartered in United States of America and employs approximately 73,000 people. It has been publicly traded since 1963.

Becton, Dickinson and Company

BDX

Market cap

$41.57B-18.3%

Revenue$21.4B+6.4%

Net income$1.1B-24.0%

Free cash flow$3.5B+17.8%

EPS (diluted)$3.95-23.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

May 7, 2026

Revenue$4.7BBeat by $42.2M EPS$2.90Beat by $0.12

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$4.9B

EPS estimate$3.14

Financials

Q2 2026

Income statement

See full

Revenue$4.7B+5.2%

Gross profit$2.2B+15.7%

Operating income$93.0M-75.7%

Net income-$311.0M-201%

EPS (diluted)-$1.11-204%

Balance sheet

See full

Cash & equivalents$1.0B+49.0%

Total debt$14.7B-16.8%

Total equity$24.1B-4.4%

Total assets$50.8B-6.7%

Cash flow

See full

Operating cash flow$671.0M—

CapEx$125.0M+9.6%

Free cash flow$546.0M—

Valuation & ratios

Valuation

See full

Market cap$41.57B-18.3%

Enterprise value$55.26B-16.7%

P/E36.5×+5.3×

P/S2×-0.5×

Profitability

See full

Gross margin46.8%+2.5pp

Operating margin10.4%+0.1pp

Net margin5.3%-2.1pp

FCF margin16.4%—

Returns & leverage

See full

Return on equity4.6%-1.3pp

Debt / equity0.6×-0.1×

Current ratio0.9×-0.2×

Segments

By segment

See full

Medical Essentials$1.6B—

Interventional$1.4B+7.4%

Connected Care$1.1B—

BioPharma Systems$590.0M—

Competitors

By market cap

Thermo Fisher Scientific$194.99B+23.4%

Abbott$164.43B-29.3%

Danaher$138.71B-2.9%

Medtronic$105.46B-6.1%

Becton, Dickinson and Company$41.6B-16.1%

Baxter International$11.6B-23.9%

Omnicell$2.1B+53.0%

InfuSystem Holdings$196.6M+49.9%

By revenue growth

Medtronic+8.4%

Omnicell+7.9%

Abbott+6.6%

Becton, Dickinson and Company+6.4%

Baxter International+5.1%

Danaher+4.0%

InfuSystem Holdings+3.5%

Thermo Fisher Scientific+2.4%

By net margin

Thermo Fisher Scientific15.19%+0.4pp

Danaher14.89%-0.9pp

Abbott13.91%-18.0pp

Medtronic13.2%-0.7pp

InfuSystem Holdings5.56%+3.2pp

Becton, Dickinson and Company5.33%-2.1pp

Omnicell1.69%+0.2pp

Baxter International-9.7%-4.5pp

Profile

Becton, Dickinson and Company (BD) is a global medical technology leader that develops, manufactures, and sells a comprehensive range of medical supplies, devices, laboratory equipment, and diagnostic products. The company focuses on improving medication management, patient safety, and clinical outcomes through advanced solutions for healthcare providers, researchers, and the pharmaceutical industry.

Competitive position

A global leader in medical technology with a dominant position in medication delivery and diagnostic specimen collection.

GeographiesNorth America, Europe, Asia-Pacific, Latin America

Customer segmentsHospitals, Clinical Laboratories, Pharmaceutical Companies, Research Institutions

Business modelManufacturing, Direct Sales, Consumables-driven recurring revenue

SuppliersRaw material suppliers (plastics, resins, metals), Electronic component manufacturers, Specialized chemical and reagent suppliers

CustomersAcute care hospitals, Reference laboratories, Retail pharmacies, Government health agencies

CountryUnited States of America

Listed1963

Employees73.0K

CEOThomas E. Polen Jr.

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitebd.com

FilingsSEC EDGAR

Ask your AI about Becton, Dickinson and Company.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Becton, Dickinson and Company's market cap?: Becton, Dickinson and Company (BDX) has a market capitalization of $41.6B and trades on NYSE.
What is Becton, Dickinson and Company's revenue and profitability?: Becton, Dickinson and Company generated $21.4B in trailing twelve-month revenue with net income of $1.1B, representing a net margin of 5.3%. Gross margin stands at 46.8%, with free cash flow of $3.5B. These figures are based on the Q1 2026 filing.
Who are Becton, Dickinson and Company's competitors?: Becton, Dickinson and Company's key competitors include Baxter International, Abbott Laboratories, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.
Who does Becton, Dickinson and Company partner with?: Becton, Dickinson and Company's notable partners include Microsoft.
What subsidiaries does Becton, Dickinson and Company have?: Becton, Dickinson and Company's subsidiaries include C. R. Bard, CareFusion.
Where is Becton, Dickinson and Company headquartered?: Becton, Dickinson and Company is headquartered in United States of America and employs approximately 73,000 people. It has been publicly traded since 1963.